BOSTON, July 10- Two former employees of rival biopharmaceutical companies were convicted on Tuesday on U.S. charges that they used their access to confidential information about drug studies to profit in the stock market through insider trading. A federal jury in Boston found Schultz Chan, a former Akebia Therapeutics Inc employee, and Songjiang Wang, who...
BOSTON, July 10- Two former employees of rival biopharmaceutical companies were convicted on Tuesday on U.S. charges that they used their access to confidential information about drug studies to profit in the stock market through insider trading. A federal jury in Boston found Schultz Chan, a former Akebia Therapeutics Inc employee, and Songjiang Wang, who...
Groupon Inc., up 47 cents to $4.83. Twitter Inc., down $2.51 to $44.14. Starbucks Corp., up 92 cents to $49.90.
*Drugmaker gets its mojo back a year after cancer study flop. LONDON, July 6- AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Yet today two-thirds of analysts tracked by Thomson Reuters recommend the stock, making it one the sector's biggest...
*Drugmaker gets its mojo back a year after cancer study flop. LONDON, July 6- AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Yet today two-thirds of analysts tracked by Thomson Reuters recommend the stock, making it one the sector's biggest...
ZURICH, June 29- Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within months. Kymriah was the first so-called chimeric antigen T-cell therapy to be approved in the United States. Kymriah is priced at $475,000 in...
June 27- The U.S. Food and Drug Administration said on Wednesday it approved Array BioPharma Inc's oral combination treatment for use in patients with the deadliest form of skin cancer. Cantor Fitzgerald analyst Mara Goldstein expects peak sales in the $500 million range for the combination drug. About 91,270 new cases of melanoma will be diagnosed and about...
June 27- The U.S. Food and Drug Administration said on Wednesday it had approved Array BioPharma Inc's oral combination treatment for use in patients with the deadliest form of skin cancer. The combination therapy, which consists of encorafenib and binimetinib, is approved http://bit.ly/2tNoOQW to treat patients with advanced melanoma associated with a...
June 27- Array BioPharma Inc said on Wednesday the U.S. Food and Drug Administration approved its combination treatment for use in patients with the deadliest form of skin cancer.
ZURICH, June 25- Swiss drugmaker Roche's hopes of having the first immunotherapy cocktail to be approved as an initial treatment for an aggressive form of lung cancer remained intact on Monday after a trial showed positive survival data. The mixture also helped patients survive longer without their disease getting worse, Sandra Horning, Roche's chief...
BOSTON, June 20- A former Puma Biotechnology Inc executive was sentenced on Wednesday to 2-1/ 4 years in prison for trading on inside information ahead of announcements by the biopharmaceutical company about a breast cancer drug it was developing. District Judge William Young in Boston after pleading guilty in November to seven counts of securities fraud for...
*Top Roche scientist to head R&D from July 1. PARIS, June 20- Sanofi missed the boat on immune system-boosting cancer drugs. The French drugmaker has hired John Reed, the former top scientist at oncology market leader Roche to head its group research operations.
June 19- Sarepta Therapeutics Inc shares jumped 60 percent on Tuesday after the drugmaker reported promising results from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy. "I have been waiting my entire 49- year career to find a therapy that dramatically reduces CK levels and creates significant levels of...
June 19- Sarepta Therapeutics Inc reported promising results on Tuesday from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy, driving the company's shares up 60 percent.
June 12- GlaxoSmithKline Plc said the president of its vaccines business, Luc Debruyne, would leave the company at the end of the year. Roger Connor, president of its global manufacturing and supply division since 2012, would replace Debruyne on September 1. Debruyne has held a number of roles during his career at GlaxoSmithKline, including general manager in...
LOS ANGELES, June 11- Billionaire Patrick Soon-Shiong plans to take an experimental cancer treatment company public this year and has begun hiring bankers, the biotechnology entrepreneur told Reuters. Later, he founded Culver City, California- based NantWorks, from which he has spun off two publicly traded companies cancer-testing company NantHealth Inc...
Mylan's shares rose 5.2 percent to $40.50 after the bell, while Amgen fell 1.7 percent to $182.30. "Mylan is thus far the only approved biosimilar, and may therefore fill the channel ahead of competition," Mizuho Securities analyst Irina Koffler said in a note. Fulphila is the second biosimilar from Mylan and Biocon to be approved in six months, after the FDA gave its...
In 2017, the FDA declined to approve Mylan's copycat version of the drug, Fulphila, and asked for more data related to manufacturing facilities of the company and its partner Biocon. Mylan's Fulphila can cause serious side effects including a rupture of the spleen, acute respiratory distress syndrome, and serious allergic reactions, the FDA said...
ZURICH, June 1- With women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to counteract sexism that it worries might become a barrier to adoption of its new medicine Aimovig. The injectable monoclonal antibody that Novartis has developed with Amgen won approval in the United States this month and on Friday...
*Tecentriq boosts survival in latest lung cancer trial. ZURICH, May 29- Roche's bid to keep Merck's cancer blockbuster Keytruda within striking distance got a lift on Tuesday when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients' survival. "The results of the IMpower130 study add to the growing...
